Principal Financial Group Inc. Has $167,000 Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Principal Financial Group Inc. cut its holdings in SI-BONE, Inc. (NASDAQ:SIBNFree Report) by 94.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,217 shares of the company’s stock after selling 186,751 shares during the period. Principal Financial Group Inc.’s holdings in SI-BONE were worth $167,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SIBN. Glenmede Trust Co. NA acquired a new stake in shares of SI-BONE in the third quarter valued at approximately $417,000. Wellington Management Group LLP raised its holdings in shares of SI-BONE by 5.4% in the third quarter. Wellington Management Group LLP now owns 605,839 shares of the company’s stock valued at $12,868,000 after purchasing an additional 31,051 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of SI-BONE by 7.2% in the third quarter. Vanguard Group Inc. now owns 2,308,516 shares of the company’s stock valued at $49,033,000 after purchasing an additional 155,121 shares during the last quarter. RiverPark Advisors LLC increased its holdings in SI-BONE by 22.6% during the fourth quarter. RiverPark Advisors LLC now owns 3,151 shares of the company’s stock worth $66,000 after buying an additional 580 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in SI-BONE by 92.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 419,940 shares of the company’s stock worth $8,815,000 after buying an additional 201,615 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Anthony J. Recupero sold 3,941 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.10, for a total value of $59,509.10. Following the completion of the sale, the insider now owns 247,592 shares of the company’s stock, valued at $3,738,639.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Anthony J. Recupero sold 3,941 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.10, for a total transaction of $59,509.10. Following the completion of the sale, the insider now owns 247,592 shares of the company’s stock, valued at $3,738,639.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,309 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $12.92, for a total transaction of $42,752.28. Following the sale, the insider now directly owns 243,629 shares of the company’s stock, valued at approximately $3,147,686.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,956 shares of company stock valued at $172,555. 5.40% of the stock is owned by company insiders.

SI-BONE Stock Up 3.8 %

SIBN stock opened at $13.49 on Tuesday. The company has a quick ratio of 8.75, a current ratio of 9.76 and a debt-to-equity ratio of 0.22. The company has a fifty day moving average price of $13.64 and a two-hundred day moving average price of $16.60. SI-BONE, Inc. has a one year low of $11.76 and a one year high of $27.86.

SI-BONE (NASDAQ:SIBNGet Free Report) last announced its earnings results on Monday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $37.87 million during the quarter, compared to analysts’ expectations of $36.45 million. SI-BONE had a negative net margin of 29.93% and a negative return on equity of 25.14%. Equities analysts anticipate that SI-BONE, Inc. will post -0.95 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on SIBN. JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of SI-BONE in a report on Tuesday, May 7th. Piper Sandler began coverage on shares of SI-BONE in a report on Thursday, March 28th. They set an “overweight” rating and a $25.00 target price on the stock. Morgan Stanley lowered their target price on shares of SI-BONE from $26.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, May 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 price objective on shares of SI-BONE in a research report on Tuesday, May 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE currently has a consensus rating of “Buy” and an average target price of $26.33.

Check Out Our Latest Research Report on SI-BONE

SI-BONE Profile

(Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Read More

Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-BONE, Inc. (NASDAQ:SIBNFree Report).

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.